CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:25:32 ON 28 JAN 2008

=> file reg

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 17:25:47 ON 28 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 JAN 2008 HIGHEST RN 1000849-38-6
DICTIONARY FILE UPDATES: 27 JAN 2008 HIGHEST RN 1000849-38-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Documents and Settings\jcho2\My Documents\10588478-a.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR




G1 Ak,Cy

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 17:26:07 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      173 TO ITERATE

100.0% PROCESSED      173 ITERATIONS                                 22 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         2671 TO     4249
PROJECTED ANSWERS:             159 TO      721

L2            22 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 17:26:26 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     3389 TO ITERATE

100.0% PROCESSED     3389 ITERATIONS                                564 ANSWERS
SEARCH TIME: 00.00.01

L3            564 SEA SSS FUL L1

=> d scan

L3    564 ANSWERS   REGISTRY  COPYRIGHT 2008 ACS on STN
IN    1,4-Benzenedicarboxamide, N-[2-[bis[2-[[[1,2-dihydro-1-methyl-2-oxo-3-
      (phenylmethoxy)-4-pyridinyl]carbonyl]amino]ethyl]amino]ethyl]-N'-(4-oxo-
      7,10,13,16,19,22,25,28,31,34,37,40-dodecaoxa-3-azahentetracont-1-yl)-2,3-
      bis(phenylmethoxy)- (9CI)
MF    C84 H112 N8 O23
```













**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=>
Uploading C:\Documents and Settings\jcho2\My Documents\10588478-b.str

L4 STRUCTURE UPLOADED

=> d l2

L2 ANSWER 1 OF 22 REGISTRY COPYRIGHT 2008 ACS on STN
RN 919772-33-1 REGISTRY
ED Entered STN: 07 Feb 2007
CN L-Alanine, N-[4-[[(2-aminoethyl)amino]carbonyl]-3-methoxybenzoyl]- (CA

INDEX NAME)
FS STEREOSEARCH
MF C14 H19 N3 O5
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l4
L4 HAS NO ANSWERS
L4 STR




G1 Ak,Cy

Structure attributes must be viewed using STN Express query preparation.

=> s l4 sss sam
SAMPLE SEARCH INITIATED 17:31:42 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 173 TO ITERATE

100.0% PROCESSED 173 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2671 TO 4249
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s l4 sss full
FULL SEARCH INITIATED 17:31:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3389 TO ITERATE

100.0% PROCESSED 3389 ITERATIONS 27 ANSWERS
SEARCH TIME: 00.00.01

L6 27 SEA SSS FUL L4

=> d scan

L6 27 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-phenoxybenzoyl]-, methyl ester
MF C27 H36 N2 O5

Absolute stereochemistry.




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> file caplus

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 362.86 | 363.07 |

FILE 'CAPLUS' ENTERED AT 17:32:05 ON 28 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Jan 2008 VOL 148 ISS 5
FILE LAST UPDATED: 27 Jan 2008 (20080127/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l6
L7 4 L6

=> d l7 1-4 bib abs hitstr

L7 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:961964 CAPLUS
DN 143:248664
TI Preparation of terephthalamide peptidomimetic compounds for therapeutic use
IN Hamilton, Andrew D.; Yin, Hang
PA Yale University, USA
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2005079541 | A2 | 20050901 | WO 2005-US5557 | 20050222 |
| | WO 2005079541 | A3 | 20051103 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2005215051 | A1 | 20050901 | AU 2005-215051 | 20050222 |
| | CA 2556447 | A1 | 20050901 | CA 2005-2556447 | 20050222 |
| | EP 1723100 | A2 | 20061122 | EP 2005-713917 | 20050222 |
| | R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU | | | | |
| | US 2007123592 | A1 | 20070531 | US 2006-588478 | 20061002 |
| PRAI | US 2004-546111P | P | 20040219 | | |
| | WO 2005-US5557 | W | 20050222 | | |

OS CASREACT 143:248664; MARPAT 143:248664
GI



I



II

AB The invention relates to compds. and pharmaceutical compns. based on terephthalamide which are proteomimetic and methods for inhibiting the interaction of an α-helical protein with another protein or binding site and for treating diseases or conditions which are modulated through these interactions. Compds. I [X is H, halo, R, OR, SR or an amino group, where R is H, (un)substituted alkyl, acyl, aryl, heteroaryl, alkylenearyl or alkyleneheteroaryl; X2, X3, X4 are independently H, halo, OH, Rc, ORc, where Rc is (un)substituted alkyl, acyl, aryl or alkylenearyl; R4 is H, (un)substituted alkyl, alkenyl or alkylene amine; R', R1a, R1b are any group given for R4 or (CH2)0-2CHR2CO2H or an alkyl ester, where R2 is independently H or (un)substituted hydrocarbon, alkoxy, ester, alkanol, alkanoic acid, amine, etc.; or N-R' or NR1aR1b form an amino acid residue] are claimed. Thus, peptidomimetic compound II, prepared via coupling reaction of L-leucine Me ester hydrochloride, showed inhibitory constant Ki = 0.781 ± 0.070 μM in a fluorescence polarization assay (binding affinity for Bcl-XL).

IT 681466-00-2P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(conformation; preparation of terephthalamide peptidomimetic compds. for therapeutic use)

RN 681466-00-2 CAPLUS

CN L-Leucine, N-[4-[[[(1S)-2-methoxy-1-methyl-2-oxoethyl](2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 681465-54-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of terephthalamide peptidomimetic compds. for therapeutic use)

RN 681465-54-3 CAPLUS

CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 681465-56-5P 681465-60-1P 681465-62-3P
681465-64-5P 681465-66-7P 681465-68-9P
681465-70-3P 681465-74-7P 852065-21-5P
852065-22-6P 852065-23-7P 852065-25-9P
852065-26-0P 852065-27-1P 852065-28-2P
852065-29-3P 852065-30-6P 852065-31-7P
852065-32-8P 852065-33-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of terephthalamide peptidomimetic compds. for therapeutic use)

RN 681465-56-5 CAPLUS
CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 681465-60-1 CAPLUS
CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-methoxybenzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 681465-62-3 CAPLUS
CN D-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-methoxybenzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 681465-64-5 CAPLUS
CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-phenoxybenzoyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 681465-66-7 CAPLUS
CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-
naphthalenyloxy)benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 681465-68-9 CAPLUS
CN L-Alanine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-
methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 681465-70-3 CAPLUS
CN L-Valine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 681465-74-7 CAPLUS
CN L-Leucine, N-[4-[[[(1S)-1-carboxy-2-methylpropyl](2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 852065-21-5 CAPLUS
CN L-Phenylalanine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 852065-22-6 CAPLUS
CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-methoxybenzoyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 852065-23-7 CAPLUS
CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-phenoxybenzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 852065-25-9 CAPLUS
CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(4-nitrophenoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 852065-26-0 CAPLUS
CN L-Alanine, N-[4-[(dimethylamino)carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 852065-27-1 CAPLUS
CN L-Leucine, N-[4-[(dimethylamino)carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 852065-28-2 CAPLUS
CN L-Phenylalanine, N-[4-[(dimethylamino)carbonyl]-2-(1-methylethoxy)benzoyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 852065-29-3 CAPLUS
CN L-Alanine, N-[4-[(diethylamino)carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 852065-30-6 CAPLUS

CN L-Leucine, N-[4-[(diethylamino)carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 852065-31-7 CAPLUS
CN L-Alanine, N-[4-[[bis(2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 852065-32-8 CAPLUS
CN L-Leucine, N-[4-[[bis(2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 852065-33-9 CAPLUS
CN L-Valine, N-[4-[[bis(2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L7 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:267006 CAPLUS
DN 142:482288
TI Terephthalamide Derivatives as Mimetics of Helical Peptides: Disruption of the Bcl-xL/Bak Interaction
AU Yin, Hang; Lee, Gui-in; Sedey, Kristine A.; Rodriguez, Johanna M.; Wang, Hong-Gang; Sebti, Said M.; Hamilton, Andrew D.
CS Department of Chemistry, Yale University, New Haven, CT, 06520-8107, USA
SO Journal of the American Chemical Society (2005), 127(15), 5463-5468
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
OS CASREACT 142:482288
GI



I



II

AB A series of Bcl-xL/Bak antagonists, based on a terephthalamide scaffold, was designed to mimic the α-helical region of the Bak peptide. These mols. showed favorable in-vitro activities in disrupting the Bcl-xL/Bak BH3 domain complex (terephthalamides I and II, Ki = 0.78 ± 0.07 and 1.85 ± 0.32 μM, resp.). Extensive structure-affinity studies demonstrated a correlation between the ability of terephthalamide derivs. to disrupt Bcl-xL/Bak complex formation and the size of variable side chains on these mols. Treatment of human HEK293 cells with the terephthalamide derivative 26 resulted in disruption of the Bcl-xL/Bax interaction in whole cells with an IC50 of 35.0 μM. Computational docking simulations and NMR expts. suggested that the binding cleft for the BH3 domain of the Bak peptide on the surface of Bcl-xL is the target area for these synthetic inhibitors.
IT 681465-54-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of terephthalamide derivs. as helical peptidomimetics and their evaluation as antagonists of Bcl-x/Bak protein interaction)
RN 681465-54-3 CAPLUS
CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 681465-56-5P 681465-58-7P 681465-60-1P
681465-62-3P 681465-64-5P 681465-68-9P
681465-70-3P 681465-74-7P 852065-21-5P
852065-22-6P 852065-23-7P 852065-24-8P
852065-25-9P 852065-26-0P 852065-27-1P
852065-28-2P 852065-29-3P 852065-30-6P
852065-31-7P 852065-32-8P 852065-33-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of terephthalamide derivs. as helical peptidomimetics and their evaluation as antagonists of Bcl-x/Bak protein interaction)

RN 681465-56-5 CAPLUS
CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 681465-58-7 CAPLUS
CN L-Leucine, N-[4-[[[(1S)-1-carboxyethyl](2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 681465-60-1 CAPLUS
CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-methoxybenzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 681465-62-3 CAPLUS
CN D-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-methoxybenzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 681465-64-5 CAPLUS
CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-phenoxybenzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 681465-68-9 CAPLUS
CN L-Alanine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 681465-70-3 CAPLUS
CN L-Valine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 681465-74-7 CAPLUS
CN L-Leucine, N-[4-[[[(1S)-1-carboxy-2-methylpropyl](2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 852065-21-5 CAPLUS
CN L-Phenylalanine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 852065-22-6 CAPLUS
CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-methoxybenzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852065-23-7 CAPLUS
CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-phenoxybenzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 852065-24-8 CAPLUS
CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(2-naphthalenyloxy)benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852065-25-9 CAPLUS
CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(4-nitrophenoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 852065-26-0 CAPLUS
CN L-Alanine, N-[4-[(dimethylamino)carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 852065-27-1 CAPLUS
CN L-Leucine, N-[4-[(dimethylamino)carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 852065-28-2 CAPLUS
CN L-Phenylalanine, N-[4-[(dimethylamino)carbonyl]-2-(1-methylethoxy)benzoyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 852065-29-3 CAPLUS
CN L-Alanine, N-[4-[(diethylamino)carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 852065-30-6 CAPLUS
CN L-Leucine, N-[4-[(diethylamino)carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 852065-31-7 CAPLUS
CN L-Alanine, N-[4-[[bis(2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 852065-32-8 CAPLUS

CN L-Leucine, N-[4-[[bis(2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 852065-33-9 CAPLUS
CN L-Valine, N-[4-[[bis(2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:189140 CAPLUS
DN 140:350050
TI Terephthalamide derivatives as mimetics of the helical region of Bak peptide target Bcl-xL protein
AU Yin, Hang; Hamilton, Andrew D.
CS Department of Chemistry, Yale University, New Haven, CT, 06511, USA
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(6), 1375-1379
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 140:350050
AB A group of novel Bcl-xL/Bak antagonists, based on a terephthalamide scaffold, were designed to mimic the α-helical region of the Bak peptide. Good in vitro inhibition potencies in disrupting the Bak/Bcl-xL complex have been observed (terephthalamide 4, Ki=0.78±0.07 μM).
IT 681465-54-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(terephthalamide derivs. as novel Bcl-xL/Bak antagonists)
RN 681465-54-3 CAPLUS
CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 681465-56-5P 681465-58-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(terephthalamide derivs. as novel Bcl-xL/Bak antagonists)
RN 681465-56-5 CAPLUS
CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 681465-58-7 CAPLUS
CN L-Leucine, N-[4-[[[(1S)-1-carboxyethyl](2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 681465-60-1 681465-62-3 681465-64-5
681465-66-7 681465-68-9 681465-70-3
681465-72-5 681465-74-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(terephthalamide derivs. as novel Bcl-xL/Bak antagonists)
RN 681465-60-1 CAPLUS
CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-methoxybenzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 681465-62-3 CAPLUS
CN D-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-methoxybenzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 681465-64-5 CAPLUS
CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-phenoxybenzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 681465-66-7 CAPLUS
CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-naphthalenyloxy)benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 681465-68-9 CAPLUS
CN L-Alanine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 681465-70-3 CAPLUS
CN L-Valine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 681465-72-5 CAPLUS
CN Benzeneacetic acid, α-[[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]amino]-, methyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 681465-74-7 CAPLUS
CN L-Leucine, N-[4-[[[(1S)-1-carboxy-2-methylpropyl](2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 681466-00-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(terephthalamide derivs. as novel Bcl-xL/Bak antagonists)
RN 681466-00-2 CAPLUS
CN L-Leucine, N-[4-[[[(1S)-2-methoxy-1-methyl-2-oxoethyl](2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:394328 CAPLUS
DN 129:67773
TI Preparation of benzamide derivatives having a vasopressin antagonistic activity
IN Setoi, Hiroyuki; Ohkawa, Takehiko; Zenkoh, Tatsuya; Sawada, Hitoshi; Sawada, Yuki; Oku, Teruo
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 332 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 9824771 | A1 | 19980611 | WO 1997-JP4192 | 19971118 |
| | W: AU, CA, CN, HU, IL, JP, KR, MX, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | AU 9749672 | A | 19980629 | AU 1997-49672 | 19971118 |
| | EP 946519 | A1 | 19991006 | EP 1997-912493 | 19971118 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI | | | | |
| | JP 2001505193 | T | 20010417 | JP 1998-521225 | 19971118 |
| | US 6207693 | B1 | 20010327 | US 1999-308662 | 19990602 |
| | US 6316482 | B1 | 20011113 | US 2000-614132 | 20000711 |
| PRAI | AU 1996-3953 | A | 19961202 | | |
| | WO 1997-JP4192 | W | 19971118 | | |
| | US 1999-308662 | A3 | 19990602 | | |

OS MARPAT 129:67773
GI



I



II

AB The title compds. [I; R1 = (un)substituted aryl, cyclo(lower)alkyl, heterocyclyl; R2 = H, lower alkyl, etc.; R3 = H, halo, OH, etc.; A = a single bond, O, NH; E = lower alkylene, lower alkenylene, etc.; X = CH:CH, CH:N, S; Y = (un)substituted aryl, condensed heterocyclyl, etc.] and their pharmaceutically acceptable salts, useful in treatment and/or prevention of hypertension, heart failure, renal insufficiency, edema, ascites, vasopressin parasecretion syndrome, hepatocirrhosis, hyponatremia, hypokalemia, diabetic, circulation disorder, cerebrovascular disease, Meniere's disease or motion sickness, were prepared Thus, the title compound II showed IC50 of 1.5 nM against vasopressin 1 receptor binding.

IT 208770-26-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzamide derivs. having a vasopressin antagonistic activity)

RN 208770-26-7 CAPLUS

CN 1,4-Benzenedicarboxamide, N4-[(2-amino-4-methylphenyl)methyl]-2-methoxy-N4-methyl-N1-(2-methyl-1H-benzimidazol-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




●2 HCl

PAGE 2-A

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT